RankAlpha logo
Back to Rankings

MPLT

MapLight TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The bull case is that MPLT has two meaningful Phase 2 readouts arriving in the same mid-August 2026 window, with prior company updates showing enrollment completion in ZEPHYR and completion of the last patient visit in IRIS, while cash runway through 2027 lowers near-term financing overhang [#SEC-8K-2026-05-14].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.7.
What can break
Binary clinical-readout risk is the dominant risk, with both ZEPHYR and IRIS expected around mid-August 2026.
Momentum
96
Value
46
Sentiment
22
Setup hits (3d)
— · Net —
AI TargetsBase $28.00 · Bull $38.00 · Bear $21.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-25 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net —
Target $41.50
Why
Momentum96 · Δ7d +0.7
Value46 · Δ7d 0.0
Sentiment22 · Δ7d +0.9
So what
Balanced signals. Wait for confirmation before sizing up.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Momentum · See technicals
Momentum
96
26% active weight
Current posture
7d trendFlat
Δ7d
+0.7
Δ21d
+6.4
Value
46
39% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.7
Sentiment
22
34% active weight
Current posture
7d trendImproving
Δ7d
+0.9
Δ21d
-11.3
Why this grade

Composite grade C. Momentum 96.3 / Value 46.4 / Sentiment 21.5

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.61B
Beta
-
Shares Out
42.62M
P/E (TTM) · Derived
-10.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-10.16
Rev YoY
-
EPS YoY
+172.5%
Gross Margin
-
Op Margin
-
Net Debt
-$299.3M
Current Ratio
22.91
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology